Karyopharm Therapeutics (KPTI) Reports Q4 Loss of $0.81/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Karyopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress
March 14, 2016 7:30 AM EDTCompany Continues to Expand its Leadership in SINETM-based Therapies with Selinexor Clinical Advancement and Presentations of Encouraging Data for Earlier Stage Pipeline Programs
Cash Expected to Fund Current R&D Plans into 2018
Several Data Readouts Expected over the Next 18 Months
Conference Call Scheduled for Today at 8:30 a.m. ET
NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and full year 2015 and commented on... More
